Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.62 SEK | +3.02% | +14.79% | +66.49% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.35M | Sales 2025 * | 343M 32.01M | Capitalization | 2.67B 250M |
---|---|---|---|---|---|
Net income 2024 * | -735M -68.66M | Net income 2025 * | -712M -66.51M | EV / Sales 2024 * | 13.2 x |
Net Debt 2024 * | 474M 44.28M | Net Debt 2025 * | 733M 68.51M | EV / Sales 2025 * | 9.94 x |
P/E ratio 2024 * |
-3.67
x | P/E ratio 2025 * |
-4.36
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | +3.85% | ||
1 week | +14.98% | ||
Current month | +49.55% | ||
1 month | +54.79% | ||
3 months | +35.93% | ||
6 months | +69.19% | ||
Current year | +65.19% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 43.62 | +3.02% | 269 665 |
24-05-22 | 42.34 | +5.11% | 242,333 |
24-05-21 | 40.28 | +4.19% | 273,944 |
24-05-20 | 38.66 | +5.92% | 163,474 |
24-05-17 | 36.5 | -3.03% | 117,719 |
Delayed Quote Nasdaq Stockholm, May 23, 2024 at 09:58 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.19% | 249M | |
+60.80% | 62.59B | |
-2.15% | 41.18B | |
+44.42% | 40.29B | |
-8.29% | 27.9B | |
+12.78% | 26.21B | |
-21.64% | 19.09B | |
+5.90% | 13.08B | |
+24.57% | 12.26B | |
+27.67% | 12.05B |
- Stock Market
- Equities
- HNSA Stock